Icariin Alleviates Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome by Improving Liver Fatty Acid Oxidation and Inhibiting Lipid Accumulation

被引:11
|
作者
Hai, Yang [1 ,2 ]
Zuo, Ling [1 ,3 ]
Wang, Meng [1 ,3 ]
Zhang, Ruoyu [1 ,3 ]
Wang, Munan [1 ,3 ]
Ren, Li [1 ,3 ]
Yang, Congwen [1 ,3 ]
Wang, Jianwei [1 ,3 ]
机构
[1] Tradit Chinese Med Key Lab Chongqing Prevent & Cur, Chongqing 400016, Peoples R China
[2] Chongqing Med Univ, Coll Basic Med, Chongqing 400016, Peoples R China
[3] Chongqing Med Univ, Coll Tradit Chinese Med, Chongqing 400016, Peoples R China
来源
MOLECULES | 2023年 / 28卷 / 02期
基金
中国国家自然科学基金;
关键词
fatty acid oxidation; icariin; liver lipid deposition; nonalcoholic fatty liver disease; polycystic ovary syndrome; DE-NOVO LIPOGENESIS; INFLAMMATION; CONTRIBUTES; METABOLISM; CYP4A; DIET;
D O I
10.3390/molecules28020517
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
(1) Background: Icariin is the main component of the Chinese herb Epimedium. A number of studies have shown that it alleviates abnormal lipid metabolism. However, it is not clear whether and how icariin can ameliorate hepatic steatosis with polycystic ovary syndrome (PCOS). This study was designed to explore the anti-hepatosteatosis effect of icariin in rats with polycystic ovary syndrome. (2) Methods: Female Sprague Dawley(SD)rats were treated with a high-fat diet and letrozole for 21 days to make nonalcoholic fatty liver disease (NAFLD) in the polycystic ovary syndrome model. Then model rats were treated with icariin (by gavage, once daily) for 28 days. Serum hormones and biochemical variables were determined by ELISA or enzyme. RNA-sequence analysis was used to enrich related target pathways. Then, quantitative Real-time PCR (qRT-PCR) and Western blot were performed to verify target genes and proteins. (3) Results: Icariin treatment reduced excess serum levels of Testosterone (T), Estradiol (E2), Luteinizing hormone (LH), Follicle-stimulating hormone (FSH), LH/FSH ratio, insulin, triglycerides (TG), and aspartate aminotransferase (AST) in high-fat diet (HFD) and letrozole fed rats. Meanwhile, icariin ameliorated HFD and letrozole-induced fatty liver, as evidenced by a reduction in excess triglyceride accumulation, vacuolization, and Oil Red O staining area in the liver of model rats. Results of RNA-sequencing, western blotting, and qRT-PCR analyses indicated that icariin up-regulated fatty acid translocase (CD36), in mitochondria, and peroxisome proliferator-activated receptor alpha (PPAR alpha) expression, which led to the enhancement of fatty acid oxidation molecules, such as cytochrome P450, family 4, subfamily a, polypeptide 3 (CYP4A3), carnitine palmitoyltransferase 1 alpha (CPT1 alpha), acyl-CoA oxidase 1 (ACOX1), medium-chain acyl-CoA dehydrogenase (MCAD), and long-chain acyl-CoA dehydrogenase (LCAD). Besides, icariin reduced lipid synthesis, which elicited stearoyl-Coenzyme A desaturase 1 (SCD1), fatty acid synthase (FASN), and acetyl-CoA (ACC). (4) Conclusion: Icariin showed an ameliorative effect on hepatic steatosis induced by HFD and letrozole, which was associated with improved fatty acid oxidation and reduced lipid accumulation in the liver.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease
    Dawson, Alison J.
    Sathyapalan, Thozhukat
    Smithson, Jacqueline A. J.
    Vince, Rebecca V.
    Coady, Anne-Marie
    Ajjan, Ramzi
    Kilpatrick, Eric S.
    Atkin, Stephen L.
    CLINICAL ENDOCRINOLOGY, 2014, 80 (06) : 843 - 849
  • [42] Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome
    Vassilatou, Evangeline
    Lafoyianni, Sophia
    Vassiliadi, Dimitra Argyro
    Ioannidis, Dimitrios
    Paschou, Stavroula A.
    Mizamtsidi, Maria
    Panagou, Maria
    Vryonidou, Andromachi
    MATURITAS, 2018, 116 : 1 - 7
  • [43] Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS)
    Spremovic Radenovic, Svetlana
    Pupovac, Miljan
    Andjic, Mladen
    Bila, Jovan
    Sreckovic, Svetlana
    Gudovic, Aleksandra
    Dragas, Biljana
    Radunovic, Nebojsa
    BIOMEDICINES, 2022, 10 (01)
  • [44] Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
    Wang, Xin
    Cao, Yuzhen
    Fu, Yunwei
    Guo, Guifang
    Zhang, Xiuying
    LIPIDS IN HEALTH AND DISEASE, 2011, 10
  • [45] Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
    Xin Wang
    Yuzhen Cao
    Yunwei Fu
    Guifang Guo
    Xiuying Zhang
    Lipids in Health and Disease, 10
  • [46] Predictivity of fatty liver index for non-alcoholic fatty liver disease in lean females with polycystic ovary syndrome
    Arikan, Didem
    Onmez, Attila
    Aksu, Erson
    Tasdemir, Nicel
    AFRICAN HEALTH SCIENCES, 2022, 22 (01) : 648 - 656
  • [47] Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis
    Huang, Rongshuang
    Guo, Fan
    Li, Yanping
    Liang, Yan
    Li, Guobo
    Fu, Ping
    Ma, Liang
    PHYTOMEDICINE, 2021, 92
  • [48] Polycystic ovary syndrome and nonalcoholic fatty liver in obese adolescents: association with metabolic risk profile
    Michaliszyn, Sara F.
    Lee, SoJung
    Tfayli, Hala
    Arslanian, Silva
    FERTILITY AND STERILITY, 2013, 100 (06) : 1745 - 1751
  • [49] Nonalcoholic fatty liver disease and the metabolic syndrome
    Marchesini, G
    Marzocchi, R
    Agostini, F
    Bugianesi, E
    CURRENT OPINION IN LIPIDOLOGY, 2005, 16 (04) : 421 - 427
  • [50] The metabolic syndrome and nonalcoholic fatty liver disease
    Collantes, R. S.
    Ong, J. P.
    Younossi, Z. M.
    PANMINERVA MEDICA, 2006, 48 (01) : 41 - 48